Ultragenyx Pharmaceutical reported $173M in Sales Revenues for its fiscal quarter ending in September of 2026.





Sales Change Date
Acadia Pharmaceuticals USD 342M 34.04M Sep/2026
Agios Pharmaceuticals USD 55.38M 10.64M Sep/2026
Alnylam Pharmaceuticals USD 1.46B 170M Sep/2026
BioCryst Pharmaceuticals USD 218.25M 188.3M Jun/2026
BioMarin Pharmaceutical USD 1.03B 40M Sep/2026
Insmed USD 524.42M 98.93M Sep/2026
Ionis Pharmaceuticals USD 243M 25M Sep/2026
Karyopharm Therapeutics USD 35.07M 987K Mar/2026
Kyowa Hakko Kirin JPY 121.3B 23.86B Sep/2026
MacroGenics USD 32.83M 12.03M Jun/2026
Moderna USD 1.31M 98.69M Sep/2026
Neurocrine Biosciences USD 1.12B 161M Sep/2026
PTC Therapeutics USD 357.8M 3.2M Sep/2026
Puma Biotechnology USD 80.54M 33.46M Sep/2024
Regeneron Pharmaceuticals USD 5.12B 830M Sep/2026
Sarepta Therapeutics USD 381.4M 19.9M Sep/2026
Ultragenyx Pharmaceutical USD 173M 41M Sep/2026
Vertex Pharmaceuticals USD 3.44B 110M Sep/2026